advisorsecurities master

AUPHAurinia Pharmaceuticals Inc

CSNasdaq (XNAS)·USD

Identity

Security key
12059
Ticker
AUPH
Type
CSCommon Stock
Exchange
Nasdaq(XNAS)
Venue group
NASDAQ
Operating MIC
XNAS
Market
stocks
Locale
us
Currency
USD
Listed
2009-10-21
Round lot
100
Active
Yes
Last seen in a load
2026-08-14 20:49
Vendor updated
2026-08-13 06:09
Ticker root / suffix
AUPH

Detail

Enriched 2026-08-14 20:47

Market cap
$2,055,640,545.6
Shares outstanding (class)
133,051,168
Shares outstanding (weighted)
133,051,168
SIC
2834 PHARMACEUTICAL PREPARATIONS
Employees
128
Location
EDMONTON, A0
Description

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Market cap and share counts drift.

Funds holding this security

Identifiers

Classification

Fund data